Safety and Effectiveness of Giving CPI-1189 to HIV-Infected Patients With AIDS Dementia

NCT00002414 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2005-06-24

No results posted yet for this study

Summary

The purpose of this study is to see if it is safe and effective to give CPI-1189 to patients with AIDS dementia.

Advanced HIV infection can cause AIDS dementia (brain damage due to HIV leading to loss of memory and muscle control). CPI-1189 may be able to postpone AIDS dementia or slow it down.

Conditions

  • HIV Infections

Interventions

DRUG

CPI-1189

Sponsors & Collaborators

  • Centaur Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Clifford DB

Study Design

Purpose
TREATMENT
Masking
DOUBLE

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00002414 on ClinicalTrials.gov